Codexis, Inc.
Financials
Valuation Metrics
Codexis, Inc.'s Market Cap is $149M. At end of 2025 it was $147M. Ranked #3057 of 3,121 in US market (top 98%), #1410 of 1,463 on NASDAQ (top 96%), #261 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 98%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $149M | US#3,057/3,121 Sec#261/266 |
| Revenue | $78M | US#2,737/3,121 Sec#135/266 |
| Net Income | $-31M | US—/3,121 Sec—/266 |
| Total Assets | $120M | US#3,051/3,121 Sec#260/266 |
| Net Assets | $33M | US#2,883/3,121 Sec#231/266 |
| Employees | 146 | US#2,554/3,121 Sec#147/266 |
| Value | ||
| P/B | 4.52x | US#2,106/3,121 Sec#130/266 |
| P/S | 1.92x | US#1,233/3,121 Sec#25/266 |
| FCF Yield | -8.18% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -93.22% | US#2,783/3,121 Sec#198/266 |
| ROA | -25.59% | US#2,856/3,121 Sec#145/266 |
| Op. Margin | -31.23% | US#2,644/3,121 Sec#104/266 |
| Revenue Growth | 35.89% | US#343/3,121 Sec#55/266 |
| Financial Health | ||
| Debt Ratio | 264.27% | US#2,011/3,121 Sec#208/266 |
| Total Debt | $73M | US#2,527/3,121 Sec#138/266 |
| FCF | $-12M | US#2,388/3,121 Sec#90/266 |
| Cash | $27M | US#2,789/3,121 Sec#249/266 |
| Current Ratio | 3.06x | US#771/3,121 Sec#189/266 |
| Performance | ||
| 1Y Return | -45.38% | US#2,841/3,121 Sec#240/266 |
| 1M Return | -15.00% | US#2,623/3,121 Sec#199/266 |
| From 52W High | -54.36% | US#2,843/3,121 Sec#226/266 |
| 1Y MDD | -64.49% | US#2,867/3,121 Sec#224/266 |
| Trading | ||
| Volume | 1,998,590 shares | US#1,268/3,121 Sec#135/266 |
| Trading Value | $3M | US#2,957/3,121 Sec#253/266 |
| Per Share | ||
| EPS | $-0.28 | US—/3,121 Sec—/266 |
| BPS | $0.30 | US#2,781/3,121 Sec#226/266 |
Company Info
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.